Table 2.
R : Sa
ratio |
MSC-AT | MSC-AT IFN-γ/TNF-α |
Os-MSC-AT | Os-MSC-AT IFN-γ/TNF-α |
---|---|---|---|---|
1 : 0.5 | 5.6 ± 1.0b | 7.2 ± 3.1 | 1.1 ± 0.2 | 0.9 ± 0.6 |
1 : 0.25 | 5.5 ± 1.5 | 5.2 ± 2.6 | 1.3 ± 0.3 | 0.8 ± 0.5 |
1 : 0.12 | 5.3 ± 1.5 | 4.7 ± 2.9 | 1.0 ± 0.3 | 1.1 ± 0.8 |
1 : 0.06 | 5.3 ± 2.0 | 5.5 ± 3.0 | 1.0 ± 0.2 | 1.3 ± 1.0 |
1 : 0.03 | 4.6 ± 1.1 | 3.9 ± 2.0 | 1.4 ± 0.3 | 1.8 ± 1.3 |
aPBMC from healthy individuals were used as responder cells towards AT-derived MSCs pretreated with IFN-γ and TNF-α (MSC-AT IFN-γ/TNF-α) or not (MSC-AT) as stimulating cells at various responder : stimulator (R : S) ratios. Similar experiments were performed with AT-derived MSCs committed to osteodifferentiation process and pretreated with IFN-γ and TNF-α (Os-MSC-AT IFN-γ/TNF-α) or not (Os-MSC-AT) as stimulating cells.
bData are mean ± s.e.m. of alloproliferation percentage obtained with 4 and 3 distinct healthy donors for MSC-AT and Os-MSC-AT experiments, respectively. This percentage is calculated considering PBMC stimulated with LCL* as 100% alloproliferation.